Gut Microbiome Modulation and Its Impact on Treatment-Resistant Depression: A Randomized Controlled Trial

Background: Major depressive disorder (MDD) affects over 300 million individuals globally, with approximately 30% demonstrating inadequate response to conventional antidepressant therapy. Emerging evidence implicates the gut-brain axis in mood regulation, suggesting that microbiome modulation may offer therapeutic potential for treatment-resistant depression (TRD).

Objective: To evaluate the efficacy and safety of targeted probiotic supplementation combined with selective serotonin reuptake inhibitors (SSRIs) in patients with treatment-resistant major depressive disorder.

Methods: This randomized, double-blind, placebo-controlled trial enrolled 412 adults with MDD who had failed to respond to at least two adequate SSRI trials. Participants were randomized 1:1 to receive either a multi-strain probiotic formulation (containing Lactobacillus helveticus R0052, Bifidobacterium longum R0175, and Lactobacillus rhamnosus R0011 at 10 billion CFU daily) or matching placebo, both combined with continued SSRI therapy for 16 weeks. Primary outcome was change in Montgomery-Åsberg Depression Rating Scale (MADRS) score from baseline to week 16. Secondary outcomes included remission rates (MADRS ≤10), response rates (≥50% MADRS reduction), anxiety symptoms, quality of life, and gut microbiome composition analyzed via 16S rRNA sequencing. Plasma and fecal biomarkers of gut-brain axis function including short-chain fatty acids, inflammatory cytokines, brain-derived neurotrophic factor (BDNF), and tryptophan metabolites were measured at baseline and weeks 8 and 16.

Results: Among 412 randomized participants (mean age 42.8 ± 11.3 years, 64.8% female), 389 (94.4%) completed the 16-week intervention. The probiotic group demonstrated significantly greater MADRS score reduction compared to placebo (mean difference -7.3 points, 95% CI: -9.8 to -4.8, p<0.001). Response rates were 52.7% in the probiotic group versus 28.4% in placebo (OR 2.81, 95% CI: 1.89-4.18, p<0.001), while remission rates were 31.6% versus 14.7% respectively (OR 2.67, 95% CI: 1.68-4.24, p<0.001). Probiotic supplementation was associated with significant increases in fecal butyrate and propionate levels, reduced systemic inflammation (IL-6, TNF-α), elevated serum BDNF, and favorable shifts in tryptophan metabolism toward serotonin synthesis. Microbiome analysis revealed increased alpha diversity and enrichment of Faecalibacterium prausnitzii and Akkermansia muciniphila in responders. The intervention was well-tolerated with no serious adverse events.

Conclusion: Targeted probiotic supplementation combined with SSRIs significantly improves depressive symptoms in treatment-resistant depression, with effects mediated through gut-brain axis modulation. These findings support the integration of microbiome-targeted therapies into treatment algorithms for refractory mood disorders.

Keywords: Treatment-resistant depression, gut microbiome, probiotics, gut-brain axis, SSRI, major depressive disorder, microbiota-gut-brain axis